Nautilus Biotechnology (NAUT) Enterprise Value (2020 - 2026)
Nautilus Biotechnology (NAUT) reported Enterprise Value of -$95.9 million for Q1 2026, up 30.94% on a YoY basis from -$73.2 million in Q1 2025, and up 7.29% sequentially from -$103.4 million in Q4 2025.
Nautilus Biotechnology (NAUT) Enterprise Value (2020 - 2026) Analysis & Trends
Nautilus Biotechnology (NAUT) has 7 years of Enterprise Value data on file, last reported at -$95.9 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value rose 30.94% year-over-year to -$95.9 million; the trailing twelve-month figure through Mar 2026 stood at -$95.9 million (up 30.94% YoY), and the FY2025 full-year result was -$103.4 million, up 20.39% from the prior year.
- Enterprise Value grew to -$95.9 million in Q1 2026, from -$103.4 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$95.9 million in Q1 2026 to a low of -$324.1 million in Q1 2022.
- A 5-year average of -$175.9 million and a median of -$167.3 million in 2023 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value tumbled 47423.79% in 2022 and jumped 48.37% in 2023, its largest moves.
- Tracing NAUT's Enterprise Value over 5 years: stood at -$184.5 million in 2022, then advanced by 5.99% to -$173.4 million in 2023, then increased by 25.1% to -$129.9 million in 2024, then climbed by 20.39% to -$103.4 million in 2025, then grew by 7.29% to -$95.9 million in 2026.
- Business Quant data shows NAUT's Enterprise Value at -$95.9 million in Q1 2026, -$103.4 million in Q4 2025, and -$131.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Nautilus Biotechnology | 224.14 Mn | 224.14 Mn | - | -95.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -95.87 Mn |
| Dec 31, 2025 | -103.41 Mn |
| Sep 30, 2025 | -131.43 Mn |
| Jun 30, 2025 | -147.87 Mn |
| Mar 31, 2025 | -138.81 Mn |
| Dec 31, 2024 | -129.89 Mn |
| Sep 30, 2024 | -140.61 Mn |
| Jun 30, 2024 | -167.44 Mn |
| Mar 31, 2024 | -181.37 Mn |
| Dec 31, 2023 | -173.42 Mn |
| Sep 30, 2023 | -183.29 Mn |
| Jun 30, 2023 | -163.30 Mn |
| Mar 31, 2023 | -167.35 Mn |
| Dec 31, 2022 | -184.47 Mn |
| Sep 30, 2022 | -257.97 Mn |
| Jun 30, 2022 | -299.34 Mn |
| Mar 31, 2022 | -324.12 Mn |
| Dec 31, 2021 | -345.73 Mn |
| Sep 30, 2021 | -347.35 Mn |
| Jun 30, 2021 | -373.14 Mn |